These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 30674264)
1. Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes. Dmitriev AV; Lagunin AA; Karasev DА; Rudik AV; Pogodin PV; Filimonov DA; Poroikov VV Curr Top Med Chem; 2019; 19(5):319-336. PubMed ID: 30674264 [TBL] [Abstract][Full Text] [Related]
2. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Min JS; Bae SK Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968 [TBL] [Abstract][Full Text] [Related]
3. [In silico prediction models of the induction of drug-metabolizing enzymes for drug discovery]. Yoshinari K; Nagai M Nihon Yakurigaku Zasshi; 2019; 153(4):186-191. PubMed ID: 30971659 [TBL] [Abstract][Full Text] [Related]
4. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Yan Z; Caldwell GW Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105 [TBL] [Abstract][Full Text] [Related]
6. Drug-drug interaction prediction using PASS. Dmitriev AV; Filimonov DA; Rudik AV; Pogodin PV; Karasev DA; Lagunin AA; Poroikov VV SAR QSAR Environ Res; 2019 Sep; 30(9):655-664. PubMed ID: 31482727 [TBL] [Abstract][Full Text] [Related]
7. Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. Lee MD; Ayanoglu E; Gong L Xenobiotica; 2006; 36(10-11):1013-80. PubMed ID: 17118918 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters. Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142 [TBL] [Abstract][Full Text] [Related]
9. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. Tornio A; Filppula AM; Backman JT Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044 [TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Riley RJ; Wilson CE Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570 [TBL] [Abstract][Full Text] [Related]
11. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792 [TBL] [Abstract][Full Text] [Related]
12. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985 [TBL] [Abstract][Full Text] [Related]
13. Computational prediction of cytochrome P450 inhibition and induction. Kato H Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468 [TBL] [Abstract][Full Text] [Related]
14. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Lu C; Liao M; Cohen L; Xia CQ Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292 [TBL] [Abstract][Full Text] [Related]
15. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance. Iga K J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336 [TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Kalgutkar AS; Obach RS; Maurer TS Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015 [TBL] [Abstract][Full Text] [Related]
17. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes. Hameed PN; Verspoor K; Kusljic S; Halgamuge S BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566 [TBL] [Abstract][Full Text] [Related]
18. In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms. Dmitriev AV; Rudik AV; Karasev DA; Pogodin PV; Lagunin AA; Filimonov DA; Poroikov VV Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924315 [TBL] [Abstract][Full Text] [Related]
19. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830 [TBL] [Abstract][Full Text] [Related]
20. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. Yoshida K; Maeda K; Konagaya A; Kusuhara H Drug Metab Dispos; 2018 Nov; 46(11):1805-1816. PubMed ID: 30135241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]